IndieBio, launched by SOSV in San Francisco in 2015, was Silicon Valley's first biotech program to offer on-site bio-labs and pre-seed investment to scientists launching startups. Between 2015 and 2025, IndieBio's 310 graduates raised $3.6 billion and established SOSV's reputation as a groundbreaking health and climate investor in fields ranging from food, agriculture, and industrial decarbonization to therapeutics and diagnostics.
At the start of 2026, SOSV rebranded IndieBio to SOSV NY and SOSV SF to reflect the expanded scope beyond biotechnology to all of deep tech, including chemistry, physics, and AI. The teams, locations, and facilities remain the same, continuing to serve founders with deeply resourced labs, offices, and event spaces. SOSV is the world's most active deep tech, pre-seed venture capital firm, with 800 active portfolio companies that had raised $7.3 billion and were valued at $18.2 billion as of early 2026.
SOSV's mission is to fund amazing deep tech founders right at inception—often their very first check. SOSV's General Partners work side-by-side with founders to help ensure they build incredible companies that have a profound impact on human and planetary health. The firm focuses on solving critical societal and environmental problems through experimentation and rapid iteration, supporting founders in fields including biotechnology, food, agriculture, industrial decarbonization, therapeutics, diagnostics, chemistry, physics, and AI.
From $250,000
On-Site Labs and Facilities
Access to deeply resourced labs, offices, and event spaces in San Francisco, New York City, and Newark, providing founders with the physical infrastructure needed to develop deep tech and biotech innovations.
Pre-Seed Investment at Inception
SOSV provides founders with their very first check, investing at the earliest stages when capital is most critical and hardest to obtain.
Hands-On Partner Support
General Partners work side-by-side with founders, offering mentorship and expertise to help build companies with profound impact on human and planetary health.
Proven Track Record
310 IndieBio graduates have raised $3.6 billion, with the broader SOSV portfolio of 800 companies valued at $18.2 billion and having raised $7.3 billion in follow-on funding.
Global Network and Diversity
SOSV's founders represent 82 nationalities operating in 58 countries, with 44% holding PhDs and 32% of portfolio companies having at least one female founder.
Investment stages
Locations
